サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
市場調査レポート
商品コード
1562408

欧州の非経口栄養剤市場の2030年予測-地域別分析-栄養剤タイプ別、エンドユーザー別

Europe Parenteral Nutrition Market Forecast to 2030 - Regional Analysis - by Nutrient Type and End User

出版日
ページ情報
英文 90 Pages
納期
即納可能 即納可能とは
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=144.87円
欧州の非経口栄養剤市場の2030年予測-地域別分析-栄養剤タイプ別、エンドユーザー別
出版日: 2024年07月04日
発行: The Insight Partners
ページ情報: 英文 90 Pages
納期: 即納可能 即納可能とは
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

欧州の非経口栄養市場は、2022年に24億463万米ドルと評価され、2030年には39億5,807万米ドルに達すると予測され、2022～2030年のCAGRは6.4%を記録すると推定されます。

栄養不良と早産の急増が欧州の非経口栄養市場を牽引

栄養不良には、栄養不足、過体重、肥満、ビタミンやミネラルの不足、食生活の乱れによる非感染性疾患などが含まれます。世界保健機関（WHO）のデータによると、2021年には19億人の成人が過体重または肥満であり、4億6,200万人が低体重です。さらに、5歳以下の子どものうち3,900万人が太りすぎ、1億4,900万人が栄養価の高い食べ物が慢性的に不足しているために発育・発達が阻害され、4,500万人が痩せすぎ（身長に対して痩せすぎ）です。さらに、5歳以下児の死亡の約45％は栄養不良に関連しています。国連国際児童緊急基金（ユニセフ）の2022年7月のデータによると、栄養不足の有病率は2019年の8.0％から2020年には9.3％に達し、2021年にはさらに9.8％に跳ね上がった。

Specialized Nutrition Europeの調査によると、2019年の欧州では、入院した成人患者の40％が栄養不良でした。2021年に発表された"A multi-centre survey on hospital malnutrition"（病院の栄養不良に関する多施設調査）と題された研究によると、英国の病院と在宅ケア環境では、患者の約11～45％が栄養不良に苦しんでいた。必要性に応じて非経口的方法で栄養補給を行うことは、ほとんどの栄養不良症例を治療する重要かつ適切な方法です。

早産とは、赤ちゃんがかなり早い段階で、つまり妊娠37週が完了する前に生まれることを指します。2023年に発表されたWHOのデータによると、2020年には世界中で1,340万件（10件に1件以上）の早産が報告されています。低所得国では平均12％の赤ちゃんが早産であるのに対し、高所得国では9％です。未熟児の多くは低体重で免疫力が未発達なため、命の危険にさらされています。未熟児出生の合併症として、または神経筋、心臓、その他の障害により、哺乳または嚥下が困難な早産児には、非経口栄養が望ましいです。出生直後の経腸経路では推定エネルギーと栄養所要量を安全に満たすことができない場合、非経口栄養（PN）は、未熟児新生児と乳児に対するルーチンの栄養ケアの一部です。

このように、小児と成人における栄養不良の大きな負担と早産児の多さが、非経口栄養製剤と製品に対する需要を促進し、市場を牽引しています。

欧州の非経口栄養剤市場概要

ドイツでは、過体重問題、肥満、栄養不良に関連する事例がいくつかあります。ロバート・コッホ研究所によると、2022年には男性の約3分の2、女性の半数以上が過体重です。栄養不足は、悪性腫瘍患者の好ましくない転帰と生活の質の低下につながります。活動性の腫瘍を有する患者はしばしば十分な食事を摂ることができないです。そのため、非経口と経腸栄養が体重減少の進行を予防または軽減するために使用されます。ドイツの科学医療協会（Association of the Scientific Medical Societies）によると、放射線性腸炎などの重度の消化管欠損を有する患者は、非経口栄養が有益です。ほとんどの場合、人工栄養によって体重と体脂肪量が安定または増加します。

さらに、ドイツではピロリ菌の感染率が高く、胃がんの重大な原因となっています。Clinical Microbiology and Infection Journal（ELSEVIER）に掲載された研究（2020年）によると、ヘリコバクター・ピロリ菌はドイツの全人口の～25％に感染し、胃炎を引き起こし、胃腺がんを合併します。さらに、ドイツは胃がんの罹患率が高いため、同国での診断が促進されています。国際がん研究機関の最新データによると、ドイツにおける胃がんの推定年齢標準化罹患率は10万人当たり7人で、粗罹患率は18.29です。上記の要因がドイツの非経口栄養剤市場を牽引しています。

欧州の非経口栄養剤市場の収益と2030年までの予測（金額）

欧州の非経口栄養剤市場のセグメンテーション

欧州の非経口栄養市場は、栄養タイプ、エンドユーザー、国に基づいてセグメント化されます。栄養タイプに基づき、欧州の非経口栄養市場は単回投与アミノ酸溶液、非経口脂質エマルジョン、炭水化物、微量元素、ビタミン・ミネラルに分類されます。単回投与アミノ酸溶液セグメントが2022年に最大の市場シェアを占めました。

エンドユーザー別では、欧州の非経口栄養市場は病院、クリニック、その他に区分されます。病院セグメントが2022年に最大の市場シェアを占めました。

国別では、欧州の非経口栄養市場は、ドイツが2022年に欧州の非経口栄養市場シェアを独占しました。

ICU Medical Inc、Grifols SA、Pfizer Inc、Otsuka Pharmaceuticals Co Ltd、Baxter International Inc、B Braun SE、Fresenius Kabi AG、Aculife Healthcare Pvt Ltd、Vifor Pharma Management AGは、欧州の非経口栄養剤市場で事業を展開する大手企業の一部です。

目次

第1章 イントロダクション

第2章 エグゼクティブサマリー

  • 主要な洞察

第3章 調査手法

  • 調査範囲
  • 2次調査
  • 1次調査

第4章 欧州の非経口栄養市場-主要産業力学

  • 市場促進要因
    • 胃腸疾患の有病率の上昇
    • 栄養不良と早産のケースの急増
  • 市場抑制要因
    • 非経口栄養システムに関連する機械的、消化管的、代謝的合併症
  • 市場機会
    • 企業による新製品開発
  • 今後の動向
    • 栄養製品の処方革新
  • 影響分析

第5章 非経口栄養剤市場-欧州市場分析

  • イントロダクション
  • 非経口栄養剤市場の売上高、2020～2030年

第6章 欧州の非経口栄養剤市場分析-栄養剤タイプ別

  • イントロダクション
  • 単回投与アミノ酸溶液
  • 非経口脂質エマルジョン
  • 炭水化物
  • 微量元素
  • ビタミンとミネラル

第7章 欧州の非経口栄養剤市場分析-エンドユーザー別

  • イントロダクション
  • 病院
  • クリニック
  • その他

第8章 欧州の非経口栄養市場：国別分析

  • 欧州
    • ドイツ
    • 英国
    • フランス
    • イタリア
    • スペイン
    • その他の欧州

第9章 業界情勢

第10章 企業プロファイル

  • ICU Medical Inc
  • Grifols SA
  • Pfizer Inc
  • Otsuka Pharmaceuticals Co Ltd
  • Baxter International Inc
  • B Braun SE
  • Fresenius Kabi AG
  • Vifor Pharma Management AG
  • Aculife Healthcare Pvt Ltd

第11章 企業プロファイル付録

図表

List Of Tables

  • Table 1. Parenteral Nutrition Market Segmentation
  • Table 2. Germany: Parenteral Nutrition Market - Revenue and Forecast to 2030(US$ Million) - by Nutrient Type
  • Table 3. Germany: Parenteral Nutrition Market - Revenue and Forecast to 2030(US$ Million) - by End User
  • Table 4. United Kingdom: Parenteral Nutrition Market - Revenue and Forecast to 2030(US$ Million) - by Nutrient Type
  • Table 5. United Kingdom: Parenteral Nutrition Market - Revenue and Forecast to 2030(US$ Million) - by End User
  • Table 6. France: Parenteral Nutrition Market - Revenue and Forecast to 2030(US$ Million) - by Nutrient Type
  • Table 7. France: Parenteral Nutrition Market - Revenue and Forecast to 2030(US$ Million) - by End User
  • Table 8. Italy: Parenteral Nutrition Market - Revenue and Forecast to 2030(US$ Million) - by Nutrient Type
  • Table 9. Italy: Parenteral Nutrition Market - Revenue and Forecast to 2030(US$ Million) - by End User
  • Table 10. Spain: Parenteral Nutrition Market - Revenue and Forecast to 2030(US$ Million) - by Nutrient Type
  • Table 11. Spain: Parenteral Nutrition Market - Revenue and Forecast to 2030(US$ Million) - by End User
  • Table 12. Rest of Europe: Parenteral Nutrition Market - Revenue and Forecast to 2030(US$ Million) - by Nutrient Type
  • Table 13. Rest of Europe: Parenteral Nutrition Market - Revenue and Forecast to 2030(US$ Million) - by End User
  • Table 14. Recent Organic Growth Strategies in the Parenteral Nutrition Market
  • Table 15. Glossary of Terms, Parenteral Nutrition Market

List Of Figures

  • Figure 1. Parenteral Nutrition Market Segmentation, By Country
  • Figure 2. Parenteral Nutrition Market: Key Industry Dynamics
  • Figure 3. Parenteral Nutrition Market: Impact Analysis of Drivers and Restraints
  • Figure 4. Parenteral Nutrition Market Revenue (US$ Mn), 2020 - 2030
  • Figure 5. Parenteral Nutrition Market Share (%) - by Nutrient Type (2022 and 2030)
  • Figure 6. Single Dose Amino Acid Solution: Parenteral Nutrition Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 7. Parenteral Lipid Emulsion: Parenteral Nutrition Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 8. Carbohydrates: Parenteral Nutrition Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 9. Trace Elements: Parenteral Nutrition Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 10. Vitamins and Minerals: Parenteral Nutrition Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 11. Parenteral Nutrition Market Share (%) - by End User (2022 and 2030)
  • Figure 12. Hospitals: Parenteral Nutrition Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 13. Clinics: Parenteral Nutrition Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 14. Others: Parenteral Nutrition Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 15. Europe: Parenteral Nutrition Market, by Key Country - Revenue (2022) (US$ Million)
  • Figure 16. Europe: Parenteral Nutrition Market Breakdown, by Key Countries, 2022 and 2030 (%)
  • Figure 17. Germany: Parenteral Nutrition Market - Revenue and Forecast to 2030(US$ Million)
  • Figure 18. United Kingdom: Parenteral Nutrition Market - Revenue and Forecast to 2030(US$ Million)
  • Figure 19. France: Parenteral Nutrition Market - Revenue and Forecast to 2030(US$ Million)
  • Figure 20. Italy: Parenteral Nutrition Market - Revenue and Forecast to 2030(US$ Million)
  • Figure 21. Spain: Parenteral Nutrition Market - Revenue and Forecast to 2030(US$ Million)
  • Figure 22. Rest of Europe: Parenteral Nutrition Market - Revenue and Forecast to 2030(US$ Million)
目次
Product Code: BMIRE00030424

The Europe parenteral nutrition market was valued at US$ 2,404.63 million in 2022 and is expected to reach US$ 3,958.07 million by 2030; it is estimated to record a CAGR of 6.4% from 2022 to 2030.

Surge in Cases of Malnutrition and Premature Births Drive Europe Parenteral Nutrition Market

Malnutrition includes being undernourished, overweight or obese, having inadequate vitamins or minerals, and having a non-communicable disease due to a bad diet. As per World Health Organization (WHO) data, ~1.9 billion adults were overweight or obese, whereas 462 million were underweight in 2021. Additionally, 39 million children under the age of 5 were overweight, 149 million had stunted growth and development as a result of a chronic lack of nutrient-rich food in their diets, and 45 million were wasted (too thin for height). Furthermore, ~45% of deaths among children aged less than 5 are associated with undernutrition. As per the July 2022 data of the United Nations International Children's Emergency Fund (UNICEF), the prevalence of undernourishment reached 9.3% in 2020 from 8.0% in 2019; it further jumped to 9.8% in 2021.

According to a Specialized Nutrition Europe study, ~40% of hospitalized adult patients were malnourished in Europe in 2019. As per a study titled "A multi-centre survey on hospital malnutrition," published in 2021, approximately 11-45% of patients in hospitals and home care settings in England suffered from malnutrition. Nutritional support delivered through parenteral methods, depending on the need, is an important and appropriate way of treating most malnutrition cases.

Preterm birth refers to a baby being born at a significantly early stage, i.e., before the completion of 37 weeks of pregnancy. As per the WHO data published in 2023, ~13.4 million preterm births (more than 1 in 10 births) were reported worldwide in 2020. On average, 12% of babies in low-income countries are born too early, compared to 9% in high-income countries. A large number of premature babies suffer from low weight and undeveloped immunity, which puts their lives at risk. Parenteral nutrition is preferred in preterm infants due to sucking or swallowing difficulties as a complication of an immature birth or due to neuromuscular, heart, or other disorders. When estimated energy and nutritional requirements cannot be safely met by enteral route right after birth, parenteral nutrition (PN) is part of the routine nutrition care for premature neonates and infants.

Thus, the huge burden of malnutrition in children and adults and the high number of preterm births drive the demand for parenteral nutrition formulae and products, which drives the market.

Europe Parenteral Nutrition Market Overview

In Germany, there are several cases related to overweight issues, obesity, and malnutrition. According to the Robert Koch Institute, approximately two-thirds of men and over half of women were overweight in 2022. Nutritional deficiencies lead to unfavorable outcomes and lower quality of life in patients with malignancies. Patients with active tumors often lack sufficient food; hence, parenteral and enteral nutrition is used to prevent or reduce progressive weight loss. According to the Association of the Scientific Medical Societies in Germany, patients with severe gastrointestinal defects, such as radiation enteritis, can benefit from parenteral nutrition. In most cases, artificial nutrition stabilizes or increases body weight and body fat mass.

Moreover, the incidence of H. pylori infection in Germany is high, which is a significant cause of gastric cancer. According to a study (2020) in the Clinical Microbiology and Infection Journal (ELSEVIER), Helicobacter pylori infected ~25% of the total population in Germany and caused gastritis that becomes more complicated with gastric adenocarcinoma. Furthermore, Germany has a significant incidence rate of stomach cancer, which promotes diagnostic procedures in the country. According to the latest data from the International Agency for Research on Cancer, the estimated age-standardized incidence rate for stomach cancer in Germany is 7 per 100,000, and the crude rate is 18.29. The abovementioned factors are driving the parenteral nutrition market in Germany.

Europe Parenteral Nutrition Market Revenue and Forecast to 2030 (US$ Million)

Europe Parenteral Nutrition Market Segmentation

The Europe parenteral nutrition market is segmented based on nutrient type, end user, and country. Based on nutrient type, the Europe parenteral nutrition market is categorized into single dose amino acid solution, parenteral lipid emulsion, carbohydrates, trace elements, and vitamins and minerals. The single dose amino acid solution segment held the largest market share in 2022.

By end user, the Europe parenteral nutrition market is segmented into hospitals, clinics, and others. The hospitals segment held the largest market share in 2022.

Based on country, the Europe parenteral nutrition market is segmented into s. Germany dominated the Europe parenteral nutrition market share in 2022.

ICU Medical Inc, Grifols SA, Pfizer Inc, Otsuka Pharmaceuticals Co Ltd, Baxter International Inc, B Braun SE, Fresenius Kabi AG, Aculife Healthcare Pvt Ltd, and Vifor Pharma Management AG are some of the leading players operating in the Europe parenteral nutrition market.

Table Of Contents

1. Introduction

  • 1.1 The Insight Partners Research Report Guidance
  • 1.2 Market Segmentation

2. Executive Summary

  • 2.1 Key Insights

3. Research Methodology

  • 3.1 Coverage
  • 3.2 Secondary Research
  • 3.3 Primary Research

4. Europe Parenteral Nutrition Market - Key Industry Dynamics

  • 4.1 Market Drivers
    • 4.1.1 Rise in Prevalence of Gastrointestinal Diseases
    • 4.1.2 Surge in Cases of Malnutrition and Premature Births
  • 4.2 Market Restraints
    • 4.2.1 Mechanical, Gastrointestinal, and Metabolic Complications Associated with Parenteral Feeding Systems
  • 4.3 Market Opportunities
    • 4.3.1 New Product Developments by Companies
  • 4.4 Future Trends
    • 4.4.1 Innovation in Formulations of Nutrition Products
  • 4.5 Impact Analysis

5. Parenteral Nutrition Market - Europe Market Analysis

  • 5.1 Overview
  • 5.2 Parenteral Nutrition Market Revenue (US$ Mn), 2020 - 2030

6. Europe Parenteral Nutrition Market Analysis - by Nutrient Type

  • 6.1 Overview
  • 6.2 Single Dose Amino Acid Solution
    • 6.2.1 Overview
    • 6.2.2 Single Dose Amino Acid Solution: Parenteral Nutrition Market - Revenue and Forecast to 2030 (US$ Million)
  • 6.3 Parenteral Lipid Emulsion
    • 6.3.1 Overview
    • 6.3.2 Parenteral Lipid Emulsion: Parenteral Nutrition Market - Revenue and Forecast to 2030 (US$ Million)
  • 6.4 Carbohydrates
    • 6.4.1 Overview
    • 6.4.2 Carbohydrates: Parenteral Nutrition Market - Revenue and Forecast to 2030 (US$ Million)
  • 6.5 Trace Elements
    • 6.5.1 Overview
    • 6.5.2 Trace Elements: Parenteral Nutrition Market - Revenue and Forecast to 2030 (US$ Million)
  • 6.6 Vitamins and Minerals
    • 6.6.1 Overview
    • 6.6.2 Vitamins and Minerals: Parenteral Nutrition Market - Revenue and Forecast to 2030 (US$ Million)

7. Europe Parenteral Nutrition Market Analysis - by End User

  • 7.1 Overview
  • 7.2 Hospitals
    • 7.2.1 Overview
    • 7.2.2 Hospitals: Parenteral Nutrition Market - Revenue and Forecast to 2030 (US$ Million)
  • 7.3 Clinics
    • 7.3.1 Overview
    • 7.3.2 Clinics: Parenteral Nutrition Market - Revenue and Forecast to 2030 (US$ Million)
  • 7.4 Others
    • 7.4.1 Overview
    • 7.4.2 Others: Parenteral Nutrition Market - Revenue and Forecast to 2030 (US$ Million)

8. Europe Parenteral Nutrition Market - Country Analysis

  • 8.1 Europe
    • 8.1.1 Europe: Parenteral Nutrition Market - Revenue and Forecast Analysis - by Country
      • 8.1.1.1 Germany: Parenteral Nutrition Market - Revenue and Forecast to 2030 (US$ Million)
        • 8.1.1.1.1 Overview
        • 8.1.1.1.2 Germany: Parenteral Nutrition Market - Revenue and Forecast to 2030 (US$ Million)
        • 8.1.1.1.3 Germany: Parenteral Nutrition Market Breakdown, by Nutrient Type
        • 8.1.1.1.4 Germany: Parenteral Nutrition Market Breakdown, by End User
      • 8.1.1.2 United Kingdom: Parenteral Nutrition Market - Revenue and Forecast to 2030 (US$ Million)
        • 8.1.1.2.1 Overview
        • 8.1.1.2.2 United Kingdom: Parenteral Nutrition Market - Revenue and Forecast to 2030 (US$ Million)
        • 8.1.1.2.3 United Kingdom: Parenteral Nutrition Market Breakdown, by Nutrient Type
        • 8.1.1.2.4 United Kingdom: Parenteral Nutrition Market Breakdown, by End User
      • 8.1.1.3 France: Parenteral Nutrition Market - Revenue and Forecast to 2030 (US$ Million)
        • 8.1.1.3.1 Overview
        • 8.1.1.3.2 France: Parenteral Nutrition Market - Revenue and Forecast to 2030 (US$ Million)
        • 8.1.1.3.3 France: Parenteral Nutrition Market Breakdown, by Nutrient Type
        • 8.1.1.3.4 France: Parenteral Nutrition Market Breakdown, by End User
      • 8.1.1.4 Italy: Parenteral Nutrition Market - Revenue and Forecast to 2030 (US$ Million)
        • 8.1.1.4.1 Overview
        • 8.1.1.4.2 Italy: Parenteral Nutrition Market - Revenue and Forecast to 2030 (US$ Million)
        • 8.1.1.4.3 Italy: Parenteral Nutrition Market Breakdown, by Nutrient Type
        • 8.1.1.4.4 Italy: Parenteral Nutrition Market Breakdown, by End User
      • 8.1.1.5 Spain: Parenteral Nutrition Market - Revenue and Forecast to 2030 (US$ Million)
        • 8.1.1.5.1 Overview
        • 8.1.1.5.2 Spain: Parenteral Nutrition Market - Revenue and Forecast to 2030 (US$ Million)
        • 8.1.1.5.3 Spain: Parenteral Nutrition Market Breakdown, by Nutrient Type
        • 8.1.1.5.4 Spain: Parenteral Nutrition Market Breakdown, by End User
      • 8.1.1.6 Rest of Europe: Parenteral Nutrition Market - Revenue and Forecast to 2030 (US$ Million)
        • 8.1.1.6.1 Overview
        • 8.1.1.6.2 Rest of Europe: Parenteral Nutrition Market - Revenue and Forecast to 2030 (US$ Million)
        • 8.1.1.6.3 Rest of Europe: Parenteral Nutrition Market Breakdown, by Nutrient Type
        • 8.1.1.6.4 Rest of Europe: Parenteral Nutrition Market Breakdown, by End User

9. Industry Landscape

  • 9.1 Overview
    • 9.1.1 Overview

10. Company Profiles

  • 10.1 ICU Medical Inc
    • 10.1.1 Key Facts
    • 10.1.2 Business Description
    • 10.1.3 Products and Services
    • 10.1.4 Financial Overview
    • 10.1.5 SWOT Analysis
    • 10.1.6 Key Developments
  • 10.2 Grifols SA
    • 10.2.1 Key Facts
    • 10.2.2 Business Description
    • 10.2.3 Products and Services
    • 10.2.4 Financial Overview
    • 10.2.5 SWOT Analysis
    • 10.2.6 Key Developments
  • 10.3 Pfizer Inc
    • 10.3.1 Key Facts
    • 10.3.2 Business Description
    • 10.3.3 Products and Services
    • 10.3.4 Financial Overview
    • 10.3.5 SWOT Analysis
    • 10.3.6 Key Developments
  • 10.4 Otsuka Pharmaceuticals Co Ltd
    • 10.4.1 Key Facts
    • 10.4.2 Business Description
    • 10.4.3 Products and Services
    • 10.4.4 Financial Overview
    • 10.4.5 SWOT Analysis
    • 10.4.6 Key Developments
  • 10.5 Baxter International Inc
    • 10.5.1 Key Facts
    • 10.5.2 Business Description
    • 10.5.3 Products and Services
    • 10.5.4 Financial Overview
    • 10.5.5 SWOT Analysis
    • 10.5.6 Key Developments
  • 10.6 B Braun SE
    • 10.6.1 Key Facts
    • 10.6.2 Business Description
    • 10.6.3 Products and Services
    • 10.6.4 Financial Overview
    • 10.6.5 SWOT Analysis
    • 10.6.6 Key Developments
  • 10.7 Fresenius Kabi AG
    • 10.7.1 Key Facts
    • 10.7.2 Business Description
    • 10.7.3 Products and Services
    • 10.7.4 Financial Overview
    • 10.7.5 SWOT Analysis
    • 10.7.6 Key Developments
  • 10.8 Vifor Pharma Management AG
    • 10.8.1 Key Facts
    • 10.8.2 Business Description
    • 10.8.3 Products and Services
    • 10.8.4 Financial Overview
    • 10.8.5 SWOT Analysis
    • 10.8.6 Key Developments
  • 10.9 Aculife Healthcare Pvt Ltd
    • 10.9.1 Key Facts
    • 10.9.2 Business Description
    • 10.9.3 Products and Services
    • 10.9.4 Financial Overview
    • 10.9.5 SWOT Analysis
    • 10.9.6 Key Developments

11. Appendix

  • 11.1 About The Insight Partners
  • 11.2 Glossary of Terms